Abstract Philadelphia-negative myeloproliferative neoplasms (MPNs) occur when there is over-production of myeloid cells stemming from hematopoietic stem cells with constitutive activation of JAK/STAT signaling, with JAK2V617F being the most commonly occurring somatic driver mutation. Chronic inflammation is a hallmark feature of MPNs and it is now evident that inflammation is not only a symptom of MPN but […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan National Blood Cancer Awareness Month is an annual event created by Congress in September 2010 to bring awareness to diseases of the blood, including chronic blood cancers known as Myeloproliferative Neoplasms (MPNs). Every three minutes someone in the United States is diagnosed with a blood cancer. Myeloproliferative Neoplasms (MPNs) blood cancer […]
MPNs and Insomnia: Tips for Better Sleep
65% of MPN, Cancer Patients report Insomnia, Sleep Problems Part 5 in a New Series: “Addressing MPN Symptoms” by Heidi Cascarano Many people struggle with sleep disturbances, and we all know that lack of quality sleep can lead to daytime fatigue, diminished quality of life, and other health problems. What’s worse is that the effects […]
Targeted therapies for Myeloproliferative Neoplasms MPNs
Abstract The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment in the treatment of MPNs, representing the first targeted treatment in this field. Despite a […]